Literature DB >> 16572267

Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke.

Martin Horan1, Vicky Newsway, Mark D Lewis, Tammy E Easter, D Aled Rees, Arti Mahto, David S Millar, Annie M Procter, Maurice F Scanlon, Ian B Wilkinson, Ian P Hall, Amanda Wheatley, John Blakey, Philip M W Bath, John R Cockcroft, Michael Krawczak, David N Cooper.   

Abstract

An increased prevalence of both hypertension and cerebrovascular stroke is apparent in growth hormone (GH) deficiency whilst hypertension is a frequent complication in acromegaly. This has suggested a possible link between GH, stature and arterial function. Since the risk of both hypertension and stroke also appears to be inversely correlated with adult height, we have instigated an exploratory study to assess whether inter-individual variation in the genes encoding human growth hormone (GH1) and the GH receptor (GHR) might be associated with an increased risk of hypertension and stroke. GH1 promoter haplotypes were found to differ significantly not only between hypertensive patients (n = 111) and controls (n = 121) but also between stroke patients (n = 155) and controls (n = 158). Intriguingly, the association between GH1 promoter haplotype and risk of hypertension was much greater in females than in males. An inverse correlation between height and central systolic blood pressure was apparent in both hypertensive patients and normal controls but was much stronger in individuals carrying at least one GH1 promoter risk haplotype. The GH1 genotype therefore constitutes a risk factor for hypertension that interacts with stature. A strong association was found between the presence of at least one GH1 risk haplotype and a family history of stroke at an early age (odds ratio: 9.07, 95% confidence interval: 1.14-72.22). Three novel GH variants (Arg16His, Phe176Cys, Cys189Arg) were identified during the course of this study. Although two exhibited markedly reduced biological activity in vitro, their clinical significance remains unclear. No association was found between GHR genotype and either hypertension or stroke, nor was any interaction noted between GHR and GH1 genotypes in terms of a disease association. However, an association between GHRd3 genotype and hypertension was observed among stroke patients, particularly females. Elevated HDL was found to be a risk factor for hypertension in individuals lacking a copy of the GHRd3 allele. Weak associations with GHR genotype were also noted for peripheral systolic and diastolic blood pressure in hypertensive patients. Although the underlying mechanisms are still unclear, our findings are consistent with a complex relationship between height, hypertension, GH1 promoter haplotype, GHR polymorphism and the risk of stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572267     DOI: 10.1007/s00439-006-0166-5

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  70 in total

Review 1.  Insulin-like growth factor-1 as a vascular protective factor.

Authors:  Elena Conti; Cinzia Carrozza; Ettore Capoluongo; Massimo Volpe; Filippo Crea; Cecilia Zuppi; Felicita Andreotti
Journal:  Circulation       Date:  2004-10-12       Impact factor: 29.690

2.  Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis.

Authors:  I B Wilkinson; S A Fuchs; I M Jansen; J C Spratt; G D Murray; J R Cockcroft; D J Webb
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

3.  Impact of alphaENaC polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study.

Authors:  Kety Hsieh; Wolfgang Lalouschek; Martin Schillinger; Georg Endler; Manuela Reisinger; Michael Janisiw; Wilfried Lang; Suzanne Cheng; Oswald Wagner; Christine Mannhalter
Journal:  Clin Chem       Date:  2005-02-25       Impact factor: 8.327

4.  Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.

Authors:  T A Elhadd; T A Abdu; J Oxtoby; G Kennedy; M McLaren; R Neary; J J Belch; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

5.  Association between the GH receptor/exon 3 genotype and the level of exon 3-positive GH-binding protein in human serum.

Authors:  B Seidel; A Glasow; M Schutt; W Kiess; Z Wu; C J Strasburger; J Kratzsch
Journal:  Eur J Endocrinol       Date:  2003-03       Impact factor: 6.664

6.  Family history of stroke in patients with transient ischemic attack in relation to hypertension and other intermediate phenotypes.

Authors:  Enrico Flossmann; Peter M Rothwell
Journal:  Stroke       Date:  2005-03-03       Impact factor: 7.914

Review 7.  Growth hormone deficiency and vascular risk.

Authors:  Roland W McCallum; John R Petrie; Anna F Dominiczak; John M C Connell
Journal:  Clin Endocrinol (Oxf)       Date:  2002-07       Impact factor: 3.478

8.  Growth hormone receptor variant (L526I) modifies plasma HDL cholesterol phenotype in familial hypercholesterolemia: intra-familial association study in an eight-generation hyperlipidemic kindred.

Authors:  Daisuke Takada; Yoichi Ezura; Shuji Ono; Yasuhiko Iino; Yasuo Katayama; Yuanpei Xin; Lily L Wu; Stacey Larringa-Shum; Susan H Stephenson; Steven C Hunt; Paul N Hopkins; Mitsuru Emi
Journal:  Am J Med Genet A       Date:  2003-08-30       Impact factor: 2.802

9.  A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway.

Authors:  Mark D Lewis; Martin Horan; David S Millar; Vicky Newsway; Tammy E Easter; Linda Fryklund; John W Gregory; Martin Norin; Cristóbal-Jorge Del Valle; Juan Pedro López-Siguero; Ramón Cañete; Luis Fernando López-Canti; Nieves Díaz-Torrado; Rafael Espino; Angels Ulied; Maurice F Scanlon; Annie M Procter; David N Cooper
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  10 in total

1.  Shared genetic architecture in the relationship between adult stature and subclinical coronary artery atherosclerosis.

Authors:  Andrea E Cassidy-Bushrow; Lawrence F Bielak; Patrick F Sheedy; Stephen T Turner; Julia S Chu; Patricia A Peyser
Journal:  Atherosclerosis       Date:  2011-08-30       Impact factor: 5.162

2.  Polymorphisms in the pituitary growth hormone gene and its receptor associated with coronary artery disease in a predisposed cohort from India.

Authors:  Arindam Maitra; Jayashree Shanker; Debabrata Dash; Prathima R Sannappa; Shibu John; Pratibha Siwach; Veena S Rao; H Sridhara; Vijay V Kakkar
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 3.  Application of serial analysis of gene expression to the study of human genetic disease.

Authors:  Martin P Horan
Journal:  Hum Genet       Date:  2009-07-10       Impact factor: 4.132

4.  Lack of an association between GHR exon 3 polymorphism and diabetic nephropathy in the Genetics of Kidneys in Diabetes (GoKinD) population.

Authors:  H F Gu; S Efendic; K Brismar
Journal:  Diabetologia       Date:  2008-09-05       Impact factor: 10.122

Review 5.  Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease.

Authors:  Santiago Rodriguez; Tom R Gaunt; Ian N M Day
Journal:  Hum Genet       Date:  2007-05-30       Impact factor: 4.132

6.  The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.

Authors:  Nese Cinar; Selcuk Dagdelen; Hikmet Yorgun; Ugur Canpolat; Giray Kabakçı; Tomris Erbas
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

7.  Characterisation of a functional intronic polymorphism in the human growth hormone (GH1) gene.

Authors:  David S Millar; Martin Horan; Nadia A Chuzhanova; David N Cooper
Journal:  Hum Genomics       Date:  2010-06       Impact factor: 4.639

8.  Adult Body Height and Cardiometabolic Disease Risk: The China National Health Survey in Shaanxi.

Authors:  Yuan Yuan; Bo Zhou; Shunan Wang; Jia Ma; Fen Dong; Min Yang; Zhixin Zhang; Wenquan Niu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-21       Impact factor: 5.555

9.  Association of growth hormone receptor gene variant with longevity in men is due to amelioration of increased mortality risk from hypertension.

Authors:  Timothy A Donlon; Randi Chen; Kamal H Masaki; D Craig Willcox; Richard C Allsopp; Bradley J Willcox; Brian J Morris
Journal:  Aging (Albany NY)       Date:  2021-06-01       Impact factor: 5.682

10.  Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height.

Authors:  Flavia Prodam; Silvia Savastio; Giulia Genoni; Deepak Babu; Mara Giordano; Roberta Ricotti; Gianluca Aimaretti; Gianni Bona; Simonetta Bellone
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.